SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?


To: Kevin Podsiadlik who wrote (312)3/14/2000 8:57:00 AM
From: Michael T Currie  Respond to of 513
 
This released a short while ago:

Alert: Avant Gets Fda Orphan Drug Status for its Complement Inhibitor Tp10 (health, NasdaqNM:AVAN)
(This is a headline-only alert, although it will likely be followed by an article soon)



To: Kevin Podsiadlik who wrote (312)3/14/2000 8:58:00 AM
From: LTK007  Read Replies (1) | Respond to of 513
 
they have FDA approved orphan drug status for TP-10